ImaRx Provides Update on TUCSON Phase I/II Clinical Trial in Acute Ische... (f this important stroke therapy. Fut...)

ImaRx Provides Update on TUCSON Phase I/II Clinical Trial in Acute Ischemic Stroke

Date:1/4/2008

f this important stroke therapy."

Future Development Plans

The Company intends to initiate its next SonoLysis clinical study in the second half of 2008. To avoid the inherent bleeding risk associated with tPA, the Company intends to conduct its future clinical trials under its SEDONA program, MRX-801 microbubbles and ultrasound, without tPA. Prior to commencing the trials, the Company intends to conduct its previously announced pre- clinical studies designed to further optimize the ultrasound delivery parameters.

"Concluding the TUCSON study ahead of schedule allows us early access to data and helps us to reduce our expenses," said Bradford A. Zakes, President and CEO of ImaRx Therapeutics. "We look forward to the continued advancement of our SonoLysis technology for stroke under our SEDONA program."

About ImaRx Therapeutics

ImaRx Therapeutics is a biopharmaceutical company developing and commercializing therapies for vascular disorders. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology. ImaRx Therapeutics' commercialization efforts are currently focused on its product, urokinase, for the treatment of acute massive pulmonary embolism.

Cautionary Statement For The Purpose Of The "Safe Harbor" Provisions Of The Private Securities Litigation Reform Act of 1995

Note: Statements made in this press release which are not historical in nature constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements include those related to our belief that the intracranial hemorrhage events, such as those observed in Cohort 2, may be reduced by eliminating tPA in our future SonoLysis clinical studies in stroke, our intention to initiate the next SonoLysis clinical study in the second half of 2008 and our intention to conduct previously announced
'/>"/>

3

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
2. IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
3. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
4. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
5. Replidyne Provides Strategic Update
6. BioCryst Provides Forodesine HCl Update
7. Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
8. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
9. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
10. Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary
11. Improved Cornea Surgery Technique Provides Enhanced Transplant Success

Post Your Comments:

ImaRx Provides Update on TUCSON Phase I/II Clinical Trial in Acute Ische...(f this important stroke therapy. Fut...),Health